Navigation Links
Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy

Abstract # 25670

ORLANDO, Fla., May 29 /PRNewswire-USNewswire/ -- The American Society of Clinical Oncology (ASCO) has selected new breast cancer research conducted at the Barbara Ann Karmanos Cancer Institute in Detroit for posting on ASCO's Web site. Karmanos' potentially ground-breaking findings identify a promising new therapeutic target for aggressive hormone receptor negative breast cancer tumors.


The research appears at and and is entitled "Enhancer of Zeste Homologue 2 (EZH-2) expression in breast cancer: a novel marker and potential target."

Karmanos scientists tested 84 cases of hormone receptor negative human breast carcinomas and discovered that the protein EZH-2 was expressed in 74 percent of those cases. Hormone receptor negative breast carcinoma is considered an aggressive cancer and one that is hard to treat. The finding suggests that EZH-2 could be an important therapeutic target in this patient population.

"We were interested in looking at a new target," said Zeina Nahleh, M.D., co-director of the Breast Oncology Multidisciplinary Team at Karmanos Cancer Institute and assistant professor of medicine in hematology and oncology at Wayne State University School of Medicine. "We wanted to see how much expression of the protein was present. We were surprised that 74 percent of tumors expressed that EZH-2 protein."

Sixty-one samples that researchers used were triple negative breast cancer cases and 23 cases were HER-2/neu positive. Scientists found that the increased expression of EZH-2 meant an increase in tumor size and an increase in lymph node metastasis.

Dr. Nahleh said that increased identification of proteins in these aggressive forms of breast cancer is needed to develop better treatments. The discovery of the high rate of EZH-2 protein expression in breast cancer cases opens up a new avenue in doing just that.

"We are extremely excited about this discovery," she said. "This is amazing work. In the future, this could be a target for therapy."

The identification of EZH-2 represents just the first step in the mission to find more proteins that cause deadly breast cancer tumors and assess them for possible therapeutic targets. There is much work ahead, according to Dr. Nahleh.

"The ground-breaking work will come if we can identify a specific method to target this EZH-2 protein and show that this approach would lead to meaningful clinical results," she said. "We have to go back and look at survival rates. We have to consider years of follow-up work and we have to look at other associated factors.

"This will hopefully lead to new targeted therapy strategies based on our new understanding of the biology of cancer."

Fellow investigators include Sudeshna Bandyopadhyay, M.D., of Wayne State University School of Medicine; Rouba Ali Fehmi, M.D., of the Karmanos Cancer Institute and Wayne State University School of Medicine; Haitham Arabi, M.D., resident of the Wayne State University School of Medicine's Department of Pathology ; Wael Sakr, M.D., of the Karmanos Cancer Institute and Wayne State University School of Medicine; Adnan Munkarah, M.D., of the Henry Ford Health System in Detroit; and Michael Kruger, statistical analyst with Wayne State University School of Medicine's Department of Obstetrics and Gynecology.

Dr. Nahleh noted that the discovery of a potential therapeutic target wouldn't be possible without the laboratory and clinical breast cancer research at Karmanos and its collaborative partnerships.

"I think this discovery highlights the importance of multidisciplinary work in oncology between clinical and scientific researchers," she said. "This is what Karmanos is all about."

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to

SOURCE Barbara Ann Karmanos Cancer Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuroscientists Offer Hope for Breast Cancer Patients Suffering From Chemobrain
2. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
3. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
4. Brain Stem Cells Can Be Awakened, Say Schepens Scientists
5. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
6. Scientists Reveal Roadmap to Brain Health That Can Be Passed Down to Future Generations: Exercise, Omega-3, Folic Acid, Vitamin B6, and Vitamin B12
7. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
8. Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
9. 42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases
10. Scientists Unmask Genetic Markers Associated With Psoriasis
11. Scientists Discover Why Teeth Form in a Single Row
Post Your Comments:
(Date:11/30/2015)... décembre 2015 MEDTEC Japon ... conférence d,Asie portant sur la conception ... manufacturière, se tiendra à ... 22 avril 2016. ... Photo - Logo ...
(Date:11/30/2015)... -- Nevro Corp. (NYSE: NVRO ), a global medical ... treatment of chronic pain, today announced that the Patent Trial ... Office (USPTO) has denied instituting an inter partes ... --> --> On ... two petitions challenging the validity of certain claims of the ...
(Date:11/30/2015)... 2015 Next week, December 2-3, BIOMEDevice ... ) co-located events covering the latest in Medtech innovation, ... will draw more than 3,000 design industry professionals to ... The events, combined show floor will host more than ... --> --> BIOMEDevice features suppliers ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... extremely stressful. At the VA Maryland Health Care System, the Caregiver Support ... patients. “Caregivers have a difficult job. Seventy-four percent report that their role ...
(Date:11/30/2015)... ... 30, 2015 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase awareness of the ... Mouth?” campaign to inform dentists that the technicians they trust could lack the ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Museum ... summer, ushering in a new era of publicly accessible automated technology. Now, by ... continue to offer guests an up-close look at the shuttle at MOSI’s main ...
(Date:11/30/2015)... Alexandria, VA (PRWEB) , ... November 30, 2015 ... ... the mesothelioma-affected community across the United States to access life-saving information ... on Malignant Mesothelioma will consist of three individual conferences in three major ...
(Date:11/30/2015)... ... 30, 2015 , ... Rick Sommer, president of Intellitec Solutions, ... of Information Systems course. Based in Wilmington Delaware, Intellitec Solutions is an established ... student in the Enterprise Resource Planning (ERP) Systems class. The course focuses on ...
Breaking Medicine News(10 mins):